Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has agreed to investigate Scotland-based Roslin Cells' GMP quality Pluripotent Stem Cells (PSC) for the development of regenerative medicines.
Subscribe to our email newsletter
Under the agreement, the US based pharma firm will evaluate GMP Cell lines of Roslin to assess specific clinical therapies’ potential.
Further commercial terms of the agreement are not disclosed.
Roslin Cells CEO Aidan Courtney said they have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy.
"They are already being used in our own collaborative research programmes and I am delighted that they will now be evaluated for potential use by Pfizer," Courtney said.